AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 222 min read

Argenx SE Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

Argenx SE reported Q3 2026 revenue of $1.75B, up from $1.15B a year ago, with net income of $506M. Nine-month revenue reached $4.61B, up from $2.93B, with net income of $1.34B. The company develops and commercializes antibody-based medicines for autoimmune diseases.

Original reporting
marketscreener.com
Published Oct 22, 2026, 6:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 7:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ARGX
Relevance
8/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

High
01

Why it matters

The earnings beat underscores strong pipeline progress and revenue growth, likely supporting a bullish stance.

02

Market read

Strong earnings from a mid‑cap biotech could lift sector sentiment and attract investor interest.

03

What to watch

Potential regulatory or reimbursement risks for new FcRn blockers could temper upside.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

argenx SE is a global immunology company known for its FcRn blocker therapy and pipeline of antibody medicines.

Market effects

Sector

Biotech and immunology sector may see broader optimism from argenx's strong results.

Regional

European biotech markets could benefit as a leading European firm reports robust growth.

Global

Highlights continued demand for antibody‑based therapies worldwide.

Counterpoint

What could challenge this read

If the market has already priced in the earnings beat, the stock could face short‑covering pull‑back.

Key entities

  • company
    argenx SE

    Immunology biotech firm reporting Q3 2026 results.

Read at source← All news

StoryArgenx posts Q3 2026 sales surge and announces Forte Biosciences acquisition

Also covered by

6 outlets

Related articles

OCT 22
$ARGXHighAI 8/10

Key facts: ARGX Q3 Sales $1.7B; FDA Priority Review for VYVGART Hytrulo

argenx (ARGX) reported Q3 2026 sales of $1.7B, up 54% YoY, with net profit of $506M. FDA granted priority review for VYVGART Hytrulo, with a PDUFA date set for February 2027. The company also announced positive Phase 3 results for VYVGART in IMNM and dermatomyositis, and plans to file an sBLA for IMNM by year-end. ARGX closed the Forte Biosciences deal, spending about $2.1B, and has cash of near $3.7B as of September 30, 2026.

tradingview.com2 min
OCT 22
$ARGXMed

Argenx says Vyvgart sales rose 54% in third quarter

Argenx reported a 54% increase in Vyvgart sales to $1.7B in Q3, treating generalized myasthenia gravis. Operating profit was $486M, below estimates. The company completed a $2.2B acquisition of Forte Biosciences, adding a drug for vitiligo and celiac disease. Operating margin declined to 28.2% due to acquisition costs, and R&D expenses are expected to reach $4B by 2026.

marketscreener.com2 min
OCT 22
$ARGXHighAI 8/10

argenx SE Reports Strong Q3 Earnings, Shares Trade Well Below GF

argenx SE (ARGX) reported Q3 2026 earnings per share of $7.80, up from $5.18 a year ago, with product sales growing 53% YoY to $1.72B. The company trades at $890.05, 44.3% below its GF Value of $1,597.83, indicating undervaluation. ARGX has a GF Score of 79, reflecting strong financial health and growth. Institutional investors show confidence, with eight gurus holding the stock.

gurufocus.com3 min
OCT 22
$ARGXHighAI 8/10

Argenx Earnings Up In Q3

Argenx (ARGX) reported Q3 earnings: net income rose to $506M from $344M YoY, EPS $7.80 vs. $5.18, operating profit $486M vs. $346M. Operating income increased to $1.75B from $1.15B. The company expects $4B in R&D and SG&A expenses for 2026. ARGX closed 2.34% higher at $890.05 on Nasdaq.

rttnews.com2 min